<p>俄亥俄州公共僱員退休系統在其最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在西方製藥服務公司（NYSE:WST - 免費報告）的股份減少了 10.9%。該機構投資者在此期間出售了 3,722 股後，持有 30,459 股該醫療器械供應商的股票。根據其最近的 SEC 文件，俄亥俄州公共僱員退休系統在西方製藥服務公司的持股價值為 9,977,000 美元。</p>
<ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
<p>其他大型投資者也買賣了該公司的股票。Whipplewood Advisors LLC 在第四季度以 25,000 美元的估值購買了西方製藥服務的新頭寸。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值購買了西方製藥服務的股份。Cornerstone Planning Group LLC 在第四季度將其在西方製藥服務的股份增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在上個季度又購買了 40 股。IFP Advisors Inc 在第四季度將其在西方製藥服務的股份增加了 150.9%。IFP Advisors Inc 現在擁有 133 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 80 股。最後，Private Trust Co. NA 在第四季度將其在西方製藥服務的股份增加了 138.6%。Private Trust Co. NA 現在擁有 136 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 79 股。目前 93.90% 的股票由機構投資者持有。</p>
<h2>西方製藥服務股價下跌 1.4%</h2>
<p>週二，WST 的股價開盤為 205.67 美元。該公司的 50 日移動平均線為 212.63 美元，200 日移動平均線為 269.89 美元。西方製藥服務公司 52 周低點為 187.43 美元，52 周高點為 352.33 美元。該公司的市值為 147.8 億美元，市盈率為 30.74，市盈增長比率為 6.74，貝塔值為 1.14。該公司的債務與股本比率為 0.08，速動比率為 2.23，流動比率為 2.79。</p>
<ul>
<li>今年將推動 S&amp;P 500 表現的因素是什麼？</li>
</ul>
<p>西方製藥服務（NYSE:WST - 獲取免費報告）最近一次發佈財報是在 4 月 24 日，週四。該醫療器械供應商報告本季度每股收益為 1.45 美元，超出分析師一致預期的 1.22 美元，超出幅度為 0.23 美元。該公司本季度的收入為 6.98 億美元，而分析師預期為 6.8524 億美元。西方製藥服務的股本回報率為 18.60%，淨利潤率為 17.03%。該公司的季度收入較去年同期增長了 0.4%。在去年同期，該公司每股收益為 1.56 美元。整體來看，研究分析師預測西方製藥服務公司今年將發佈 6.62 美元的每股收益。</p>
<h2>西方製藥服務股息公告</h2>
<p>該公司最近還宣佈了一項季度股息，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）登記的股東將獲得每股 0.21 美元的股息。這相當於年化股息為 0.84 美元，收益率為 0.41%。除息日期為 7 月 30 日（星期三）。西方製藥服務的派息比率目前為 13.19%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
<p>WST 已成為幾份研究分析師報告的主題。Stephens 在 4 月 21 日（星期一）的研究報告中將西方製藥服務的評級上調至 “強力買入”。華爾街 Zen 在 2 月 27 日（星期四）的研究報告中將西方製藥服務的評級從 “買入” 下調至 “持有”。花旗集團在週四的研究報告中重申了對西方製藥服務股票的 “買入” 評級。Evercore ISI 在 3 月 18 日（星期二）的研究報告中開始覆蓋西方製藥服務，併為該公司設定了 “跑贏大盤” 的評級和 275.00 美元的目標價。最後，KeyCorp 在 2 月 14 日（星期五）的研究報告中將西方製藥服務的目標價從 470.00 美元下調至 325.00 美元，併為該公司設定了 “增持” 評級。兩位投資分析師對該股票給予了 “持有” 評級，六位給予了 “買入” 評級，一位給予了 “強力買入” 評級。根據 MarketBeat.com 的數據，西方製藥服務目前的平均評級為 “適度買入”，平均目標價為 332.50 美元。</p>
<p><strong>查看我們對西方製藥服務的最新分析</strong></p>
<h2>西方製藥服務公司簡介</h2>
<p>（免費報告）</p>
<p>西方製藥服務公司設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統，業務覆蓋美洲、歐洲、中東、非洲和亞太地區。該公司分為兩個部門，專有產品和合同製造產品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過西方製藥服務</li>
<li>投資石油股票的方式和原因</li>
<li>Workday 股價暴跌：對 AI 投資者來説是自動買入</li>
<li>上升趨勢股票解析：學習如何利用上升趨勢進行交易</li>
<li>MercadoLibre 股價飆升——你應該等待更好的入場時機嗎？</li>
<li>專家股票交易心理技巧</li>
<li>對市場有疑慮？3 只股票可應對恐懼、不確定性和懷疑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
<p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
<p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西氏醫藥服務

<p>俄亥俄州公共僱員退休系統減少了對西氏醫藥服務公司（NYSE:WST）10.9% 的持股，在第四季度出售了 3,722 股，剩餘持股為 30,459 股，價值約為 998 萬美元。其他投資者也調整了在該公司的持倉。西氏醫藥的股票開盤價為 205.67 美元，市值為 147.8 億美元，市盈率為 30.74。該公司最近報告每股收益為 1.45 美元，超出預期，並宣佈季度股息為每股 0.21 美元</p>

<p>Public Employees Retirement System of Ohio cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,459 shares of the medical instruments supplier's stock after selling 3,722 shares during the period. Public Employees Retirement System of Ohio's holdings in West Pharmaceutical Services were worth $9,977,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>俄亥俄州公共僱員退休系統在其最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在西方製藥服務公司（NYSE:WST - 免費報告）的股份減少了 10.9%。該機構投資者在此期間出售了 3,722 股後，持有 30,459 股該醫療器械供應商的股票。根據其最近的 SEC 文件，俄亥俄州公共僱員退休系統在西方製藥服務公司的持股價值為 9,977,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潛力增加股息的股息冠軍</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Whipplewood Advisors LLC bought a new position in West Pharmaceutical Services during the 4th quarter valued at $25,000. Centricity Wealth Management LLC purchased a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $35,000. Cornerstone Planning Group LLC increased its position in shares of West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 40 shares during the last quarter. IFP Advisors Inc increased its position in shares of West Pharmaceutical Services by 150.9% during the 4th quarter. IFP Advisors Inc now owns 133 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 80 shares during the last quarter. Finally, Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 138.6% during the 4th quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 79 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者也買賣了該公司的股票。Whipplewood Advisors LLC 在第四季度以 25,000 美元的估值購買了西方製藥服務的新頭寸。Centricity Wealth Management LLC 在第四季度以 35,000 美元的估值購買了西方製藥服務的股份。Cornerstone Planning Group LLC 在第四季度將其在西方製藥服務的股份增加了 57.1%。Cornerstone Planning Group LLC 現在擁有 110 股該醫療器械供應商的股票，價值 38,000 美元，此前在上個季度又購買了 40 股。IFP Advisors Inc 在第四季度將其在西方製藥服務的股份增加了 150.9%。IFP Advisors Inc 現在擁有 133 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 80 股。最後，Private Trust Co. NA 在第四季度將其在西方製藥服務的股份增加了 138.6%。Private Trust Co. NA 現在擁有 136 股該醫療器械供應商的股票，價值 45,000 美元，此前在上個季度又購買了 79 股。目前 93.90% 的股票由機構投資者持有。</p>
</div><h2>West Pharmaceutical Services Trading Down 1.4%</h2>
<div class="lb-trans"><h2>西方製藥服務股價下跌 1.4%</h2>
</div><p>Shares of WST opened at $205.67 on Tuesday. The business has a 50-day moving average of $212.63 and a 200 day moving average of $269.89. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $352.33. The firm has a market cap of $14.78 billion, a P/E ratio of 30.74, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79.</p>
<div class="lb-trans"><p>週二，WST 的股價開盤為 205.67 美元。該公司的 50 日移動平均線為 212.63 美元，200 日移動平均線為 269.89 美元。西方製藥服務公司 52 周低點為 187.43 美元，52 周高點為 352.33 美元。該公司的市值為 147.8 億美元，市盈率為 30.74，市盈增長比率為 6.74，貝塔值為 1.14。該公司的債務與股本比率為 0.08，速動比率為 2.23，流動比率為 2.79。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年將推動 S&amp;P 500 表現的因素是什麼？</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.23. The business had revenue of $698.00 million during the quarter, compared to analyst estimates of $685.24 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The company's quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 EPS. As a group, research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.</p>
<div class="lb-trans"><p>西方製藥服務（NYSE:WST - 獲取免費報告）最近一次發佈財報是在 4 月 24 日，週四。該醫療器械供應商報告本季度每股收益為 1.45 美元，超出分析師一致預期的 1.22 美元，超出幅度為 0.23 美元。該公司本季度的收入為 6.98 億美元，而分析師預期為 6.8524 億美元。西方製藥服務的股本回報率為 18.60%，淨利潤率為 17.03%。該公司的季度收入較去年同期增長了 0.4%。在去年同期，該公司每股收益為 1.56 美元。整體來看，研究分析師預測西方製藥服務公司今年將發佈 6.62 美元的每股收益。</p>
</div><h2>West Pharmaceutical Services Dividend Announcement</h2>
<div class="lb-trans"><h2>西方製藥服務股息公告</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 6th. Shareholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Wednesday, July 30th. West Pharmaceutical Services's payout ratio is presently 13.19%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 8 月 6 日（星期三）支付。7 月 30 日（星期三）登記的股東將獲得每股 0.21 美元的股息。這相當於年化股息為 0.84 美元，收益率為 0.41%。除息日期為 7 月 30 日（星期三）。西方製藥服務的派息比率目前為 13.19%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增長的醫療保健股票</li>
</ul>
</div><p>WST has been the subject of several research analyst reports. Stephens raised West Pharmaceutical Services to a &#34;strong-buy&#34; rating in a research report on Monday, April 21st. Wall Street Zen lowered West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, February 27th. Citigroup reaffirmed a &#34;buy&#34; rating on shares of West Pharmaceutical Services in a research report on Thursday. Evercore ISI initiated coverage on West Pharmaceutical Services in a research report on Tuesday, March 18th. They set an &#34;outperform&#34; rating and a $275.00 target price for the company. Finally, KeyCorp decreased their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $332.50.</p>
<div class="lb-trans"><p>WST 已成為幾份研究分析師報告的主題。Stephens 在 4 月 21 日（星期一）的研究報告中將西方製藥服務的評級上調至 “強力買入”。華爾街 Zen 在 2 月 27 日（星期四）的研究報告中將西方製藥服務的評級從 “買入” 下調至 “持有”。花旗集團在週四的研究報告中重申了對西方製藥服務股票的 “買入” 評級。Evercore ISI 在 3 月 18 日（星期二）的研究報告中開始覆蓋西方製藥服務，併為該公司設定了 “跑贏大盤” 的評級和 275.00 美元的目標價。最後，KeyCorp 在 2 月 14 日（星期五）的研究報告中將西方製藥服務的目標價從 470.00 美元下調至 325.00 美元，併為該公司設定了 “增持” 評級。兩位投資分析師對該股票給予了 “持有” 評級，六位給予了 “買入” 評級，一位給予了 “強力買入” 評級。根據 MarketBeat.com 的數據，西方製藥服務目前的平均評級為 “適度買入”，平均目標價為 332.50 美元。</p>
</div><p><strong>View Our Latest Analysis on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>查看我們對西方製藥服務的最新分析</strong></p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西方製藥服務公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西方製藥服務公司設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統，業務覆蓋美洲、歐洲、中東、非洲和亞太地區。該公司分為兩個部門，專有產品和合同製造產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過西方製藥服務</li>
<li>投資石油股票的方式和原因</li>
<li>Workday 股價暴跌：對 AI 投資者來説是自動買入</li>
<li>上升趨勢股票解析：學習如何利用上升趨勢進行交易</li>
<li>MercadoLibre 股價飆升——你應該等待更好的入場時機嗎？</li>
<li>專家股票交易心理技巧</li>
<li>對市場有疑慮？3 只股票可應對恐懼、不確定性和懷疑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在西氏醫藥服務嗎？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮西氏醫藥服務之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而西氏醫藥服務並不在名單上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然西氏醫藥服務目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

俄亥俄州公共僱員退休系統出售了 3,722 股西氏醫藥服務公司（NYSE:WST）的股票